Particle Detection in Injectable Pharmaceuticals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current particle control and inspection strategies for injectable pharmaceutical compositions do not adequately consider the safety and toxicology implications of particles, potentially risking patient health due to incomplete assessment of particle size and material composition.
Innovation Solution
Methods are developed to detect and analyze particles in injectable compositions, accepting them if the largest particle's size and mass fall within specific ranges, leveraging historical data and toxicology evaluations to ensure patient safety, particularly for compositions like etanercept, darbepoetin, and pegfilgrastim, by specifying acceptable dimensions and materials for particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current particle control and inspection strategies are used, then manufacturing processes can be simplified, but patient safety is compromised due to inadequate assessment of particle size and material composition
Solution Approach 1:
The patent applies parameter changes by establishing specific numerical criteria for particle size (length, width, height dimensions) and mass thresholds that differentiate acceptable from unacceptable particles. Different parameter sets are provided for various particle materials (e.g., acrylic, aluminum, glass, metal), allowing the inspection strategy to adapt particle acceptance criteria based on material properties while maintaining a structured, manageable complexity level.
Solution Approach 2:
The patent creates a reference database of acceptable particle characteristics based on historical data and toxicology evaluations. This reference copy allows the inspection strategy to compare detected particles against pre-established safety thresholds without requiring complex real-time analysis, thereby maintaining patient safety while simplifying the inspection process through standardized comparison criteria.
2Reliability
If particle size and mass ranges are strictly enforced, then patient safety is improved, but manufacturing flexibility is reduced
Solution Approach 1:
The patent applies local quality by providing different particle size and mass acceptance criteria for different particle materials. Rather than using a single uniform standard for all particles, the invention tailors specific dimensional and mass thresholds to the particular material properties (e.g., density, composition) of each particle type, thereby maintaining manufacturing flexibility while ensuring patient safety through material-specific standards.
Solution Approach 2:
The patent implements partial action by focusing inspection and control efforts on particles that exceed specific size and mass thresholds, rather than requiring comprehensive control of all particles. The strategy accepts particles within defined safe ranges while requiring rejection only of particles exceeding critical thresholds, thereby maintaining manufacturing flexibility while addressing the most critical safety concerns.
3Reliability
If comprehensive particle analysis is performed, then patient safety is enhanced, but inspection time and resources are increased
Solution Approach 1:
The patent replaces complex mechanical inspection systems with a standardized decision-making framework based on pre-established particle size and mass criteria. Instead of requiring sophisticated real-time analysis equipment, the invention uses clear, pre-defined thresholds that can be applied through simple measurement and comparison processes, thereby enhancing patient safety through comprehensive analysis while minimizing inspection time and resource requirements.
Solution Approach 2:
The patent applies preliminary action by pre-establishing particle size and mass acceptance criteria based on historical data and toxicology evaluations before the actual inspection process. This preliminary preparation of reference standards allows for rapid, efficient inspection by simply comparing detected particles against pre-defined thresholds, thereby enhancing patient safety through comprehensive evaluation while minimizing inspection time.
Data Source
AI summary
The invention relates to methods for making injectable pharmaceutical compositions wherein particles present in the compositions are detected and analyzed, and the acceptance of the compositions is determined based on chemical and physical properties as well as toxicology and patient risks associated of the particles.